ATE552831T1 - Bionano-komposite mit verzögerter freisetzung, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Bionano-komposite mit verzögerter freisetzung, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
ATE552831T1
ATE552831T1 AT08719112T AT08719112T ATE552831T1 AT E552831 T1 ATE552831 T1 AT E552831T1 AT 08719112 T AT08719112 T AT 08719112T AT 08719112 T AT08719112 T AT 08719112T AT E552831 T1 ATE552831 T1 AT E552831T1
Authority
AT
Austria
Prior art keywords
sustained release
bionano
composites
production
nanocomposite
Prior art date
Application number
AT08719112T
Other languages
English (en)
Inventor
Imre Dekany
Marta Szekeres
Zsolt Pallai
Laszlo Bali
Original Assignee
Univ Szegedi
Pannonpharma Gyogyszergyarto Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Szegedi, Pannonpharma Gyogyszergyarto Kft filed Critical Univ Szegedi
Application granted granted Critical
Publication of ATE552831T1 publication Critical patent/ATE552831T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08719112T 2007-03-08 2008-03-07 Bionano-komposite mit verzögerter freisetzung, verfahren zu ihrer herstellung und ihre verwendung ATE552831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700203A HUP0700203A2 (en) 2007-03-08 2007-03-08 Sustained release, core-shell structure precipitated citokine bionanocomposit, a process for producing the same and use thereof
PCT/HU2008/000028 WO2008107729A1 (en) 2007-03-08 2008-03-07 Sustained release bionanocomposites, a process for producing the same and use thereof

Publications (1)

Publication Number Publication Date
ATE552831T1 true ATE552831T1 (de) 2012-04-15

Family

ID=89987384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08719112T ATE552831T1 (de) 2007-03-08 2008-03-07 Bionano-komposite mit verzögerter freisetzung, verfahren zu ihrer herstellung und ihre verwendung

Country Status (4)

Country Link
EP (1) EP2170302B1 (de)
AT (1) ATE552831T1 (de)
HU (1) HUP0700203A2 (de)
WO (1) WO2008107729A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
EP2417968A1 (de) 2010-07-29 2012-02-15 Consorzio per il Centro di Biomedicina Molecolare Scrl Partikel mit Cytokinen, Antikörpern und Polymeren und deren Verwendung als Arzneimittel zur Behandlung von Krebs
EP2604288A1 (de) * 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoteilchen und ihre Verwendungen
HU231076B1 (hu) * 2015-07-31 2020-06-29 Szegedi Tudományegyetem Hatóanyagoknak a központi idegrendszerben történő szabályozott leadására alkalmas nanokompozit, eljárás annak előállítására és alkalmazása
CN113397032B (zh) * 2021-05-24 2023-03-10 江苏省农业科学院 基于牛蒡糖蛋白的营养素递送体系及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20060228419A1 (en) * 2005-04-07 2006-10-12 Solubest Ltd. Solvent-free process for preparation of hydrophilic dispersions of nanoparticles of inclusion complexes

Also Published As

Publication number Publication date
HU0700203D0 (en) 2007-05-02
EP2170302A1 (de) 2010-04-07
EP2170302B1 (de) 2012-04-11
HUP0700203A2 (en) 2008-12-29
WO2008107729A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
ATE552831T1 (de) Bionano-komposite mit verzögerter freisetzung, verfahren zu ihrer herstellung und ihre verwendung
TW200734268A (en) Nanowire structures comprising carbon
MXPA06001267A (es) Microcapsulas.
WO2005118702A3 (en) Unagglomerated core/shell nanocomposite particles
CN104275164B (zh) 一种废水处理用氧化石墨烯多孔复合材料及其制备方法
DE60232773D1 (de) Verfahren zur Herstellung von Membran-Elektrode-Anordnungen für Brennstoffzellen
EP1970040A4 (de) Verfahren zur herstellung von arzneihaltigen wachs-matrix-teilchen, bei dem verfahren zu verwendender extrudierer und cilostazol-enthaltendes präparat mit verzögerter freisetzung
WO2007077217A3 (en) Oligopeptide-free cell culture media
WO2006125620A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2006011811A3 (en) Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process
MX2009005042A (es) Metodo para produccion de minisuspoemulsion o suspension de particulas de nucleo/coraza submicronicas.
JP2007508034A5 (de)
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
MX347518B (es) Microcapsula.
TW200704594A (en) Acidic zirconia sol and production process thereof
ATE497509T1 (de) Elektrosterisch stabilisierte wässrige polyurethan-harze, verfahren zu ihrer herstellung und deren verwendung
DE60000974D1 (de) Kontinuierliches schmelzverfahren zur herstellung von ionenleitenden gegenständen
TW200626734A (en) Vapour-deposition material for the production of layers of high refractive index
EP1936723A4 (de) Brennstoffbatteriezelle und prozess zu ihrer herstellung
ATE448221T1 (de) Verfahren zur herstellung von 1,3,4,5-tetrahydro- 2h-3-benzazepin-2-on-derivaten und dessen anwendung in der herstellung von ivabradin sowie dessen pharmazeutisch verträglichen salze
ATE538246T1 (de) Rohpapier und verfahren zu dessen herstellung
EP1429408A4 (de) Vereinigung einer elektrolytmembran/-elektrode für eine brennstoffzelle und prozess zu ihrer herstellung
TW200708581A (en) Catalyst ink, process for making catalyst ink and for preparing catalyst coated membranes
BR112015008313A8 (pt) processo
WO2006078193A8 (fr) Polybenzimidasoles substitues en benzimidazoles utilises comme matiere de base dans la fabrication de membranes conductrices de protons